A recent study indicates that individuals who stop using new slimming jabs like Mounjaro or Wegovy tend to recover shed pounds much more quickly than those who end traditional lifestyle regimens.
Research printed in a major health publication demonstrates that while obese people can lose a large proportion of their total mass while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying such medications must be cognizant of the risk of quick weight regain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to starting weight in about 18 months.
Weighing Approaches
The study, which reviewed dozens of trials involving over 9,000 of participants, contrasted the effects of these new drugs with other pills.
The team point out that individuals who lose weight through dieting usually have a less rapid weight regain—perhaps 0.1 kg a month—after stopping.
The Reason for the Fast Regain
Experts believe the mechanism of the jabs accounts for the heightened rebound.
These medications copy a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone levels far above than normal might result in the body to produce less of its own natural GLP-1, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating a significant risk."
An Ongoing Condition?
Health authorities advise the injections for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, considering the high risk of relapse, the therapy might need to be life-long.
This perspective is echoed by drug manufacturers, who state that the findings "underscore the long-term nature of excess weight," akin to managing conditions like high blood pressure.
User Experiences
Users who have discontinued the jabs explain a intense resurgence of appetite.
"It was like a switch that goes on and I was suddenly starving," recalled one woman.
This difficulty is worsened if users have not established lasting dietary or behavioural changes during treatment.
Growing Adoption
Survey data suggest that millions of people in the UK have tried these injections in the past year, with interest continuing to grow.
- Use is greater among women compared to males.
- The middle-aged age group shows the greatest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
In conclusion, researchers stress that while GLP-1 drugs are potent tools for weight loss, they are not a standalone solution and long-term success likely depends on ongoing behavioural support.
